henagliflozin + retagliptin + metformin (Shandong Shengdi Pharmaceutical)

HR20031 is a fixed-dose combination (FDC) tablet developed by Shandong Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Pharmaceuticals, for the management of type 2 diabetes mellitus. The product integrates three distinct glucose-lowering agents: henagliflozin (a selective SGLT2 inhibitor), retagliptin (a DPP-4 inhibitor), and metformin hydrochloride (a biguanide) in an extended-release formulation. Henagliflozin works by inhibiting renal glucose reabsorption in the proximal tubules, leading to glycosuria. Retagliptin prevents the degradation of incretin hormones like GLP-1, thereby stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner. Metformin primarily reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity. This triple combination is designed to provide comprehensive glycemic control by addressing multiple pathophysiological defects in type 2 diabetes.